Niagen Bioscience, Inc. (NAGE) Market Cap & Valuation Ratios
Niagen Bioscience, Inc. (NAGE) has a market cap of $192.3M, a trailing P/E of 13.5 and a price-to-sales ratio of 1.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAGENiagen Bioscience, Inc.Follow NAGE — free
—
Price chart with a free account
- Market cap
- 192.3M
- P/E TTM
- 13.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 10 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NAGE | 0.2 | 13.5 | 1.0 | 11.3 | 3.0% | +11% | 8% | 102% |
| PALI | 0.2 | — | — | — | — | — | — | — |
| LXEO | 0.2 | — | — | — | — | — | — | -78% |
| KROS | 0.2 | — | — | — | — | -94% | — | -956% |
| IKT | 0.2 | — | — | — | — | — | — | -54% |
| ALEC | 0.2 | — | 3.0 | — | — | -83% | — | — |
| ADCT | 0.2 | — | 1.0 | — | — | +3% | -125% | — |
| KRRO | 0.2 | — | 25.8 | — | — | -62% | — | -138% |
| TRDA | 0.2 | — | 15.5 | — | — | -94% | — | -80% |
| SION | 0.2 | — | — | — | — | — | — | -44% |
| CHRS | 0.2 | — | 1.7 | — | — | +61% | -312% | — |
| Median of these 10 | — | 3.0 | — | — | -72% | -218% | -79% |
; EV/Sales 1.0 vs. 3.0. NAGE's own P/E sits at the 4th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesNiagen Bioscience, Inc. — questions
- What is Niagen Bioscience, Inc.'s market cap?
- $192.3M.
- What is Niagen Bioscience, Inc.'s P/E ratio?
- 13.5 on trailing twelve-month earnings to 2026-06-30.
- What is Niagen Bioscience, Inc.'s price-to-sales ratio?
- 1.5.
Every figure on this page comes from Niagen Bioscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.